Your shopping cart is currently empty

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | - | In Stock | |
| 5 mg | $691 | - | In Stock | |
| 10 mg | $997 | - | In Stock | |
| 25 mg | $1,480 | - | In Stock | |
| 50 mg | Preferential | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $1,190 | - | In Stock |
| Description | Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research. |
| In vitro | METHODS: Lys-SMCC-DM1, DXd (1), and DXd (2) were simultaneously subjected to parallel artificial membrane permeability assay (PAMPA) using the Lys-SMCC-DM1 Freedom EVO200 system. RESULTS: Lys-SMCC-DM1 has low permeability. [1] METHODS: MDCKII/SLC46A3 dC cells were treated with Lys-SMCC-DM1 (5 µM) for 30 min, and a cellular uptake assay was performed to verify whether SLC46A3 directly transported Lys-SMCC-DM1. RESULTS: SLC46A3 directly recognized and transported Lys-SMCC-DM1 and mediated the cytotoxic effects of T-DM1. [2] |
| Synonyms | Lys-Nε-MCC-DM1 |
| Molecular Weight | 1103.71 |
| Formula | C53H75ClN6O15S |
| Cas No. | 1281816-04-3 |
| Smiles | C[C@]12[C@@](O1)([C@H](C)[C@@]3(C[C@](O)([C@H](OC)/C=C/C=C(\C)/CC4=CC(N(C)C(=O)C[C@@H]2OC([C@@H](N(C(CCS[C@@H]5C(=O)N(C[C@@H]6CC[C@@H](C(NCCCC[C@@H](C(O)=O)N)=O)CC6)C(=O)C5)=O)C)C)=O)=C(Cl)C(OC)=C4)NC(=O)O3)[H])[H] |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (54.36 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.